Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized Trial
Richard G. Wunderink(Northwestern University), Steven M. Opal(Brown University), Antonio Artigas(Instituto de Salud Carlos III), Thierry Dugernier(Clinique Saint Pierre), Christian Zwingelstein(Novartis (Switzerland)), D. Perrotin(Université de Tours), Christopher J. Doig(Alberta Health Services), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Steven P. LaRosa(Eli Lilly (United States)), Bruno François(Inserm), Guoqin Su(Novartis (Switzerland)), Meryl H. Mendelson(Novartis (Switzerland)), Jorge San Juan(Hospital Muñiz), Suzana M Lobo(Faculdade de Medicina de São José do Rio Preto), Jean-François Dhainaut, Luis Otero Vidal(Thorax Foundation), Pierre-François Laterre(UCLouvain), Sung Chul Hwang(Seoul National University Bundang Hospital)
American Journal of Respiratory and Critical Care Medicine
February 4, 2011
Cited by 128
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k